What are the recommended dosing, monitoring, contraindications, adverse effects, and alternative therapies for axitinib in advanced renal cell carcinoma?

Axitinib in Advanced Renal Cell Carcinoma

Recommended Dosing

Start axitinib at 5 mg orally twice daily with or without food, and titrate upward to 7 mg then 10 mg twice daily at 2-week intervals if the patient tolerates the current dose without significant adverse effects, particularly if diastolic blood pressure remains <90 mmHg 1.

• The dose escalation strategy is supported by pharmacodynamic data showing that higher plasma exposure and diastolic blood pressure ≥90 mmHg correlate with improved progression-free survival, overall survival, and response rates 2
• Approximately 42% of patients require dose reductions, while 11% successfully escalate doses 3
• Dose reductions do not appear to negatively impact efficacy; real-world data suggest patients with dose reductions may have improved one-year overall survival (92.9% vs 80%) 4

Dosing Modifications

For hepatic impairment: Reduce starting dose to 2 mg twice daily in moderate hepatic impairment (Child-Pugh Class B), as axitinib AUC increases 2-fold in this population 1, 5. No adjustment needed for mild impairment.

For drug interactions:

• Strong CYP3A4/5 inhibitors (ketoconazole): Reduce dose by approximately 50% due to 2-fold increase in exposure 5
• Strong CYP3A4/5 inducers (rifampin): Avoid concomitant use, as they decrease axitinib exposure by 71-79% 5

For patients unable to swallow: An oral suspension can be prepared; crushing tablets is not recommended 6

Clinical Use and Indications

Axitinib is FDA-approved and guideline-recommended in two distinct settings:

First-Line Therapy (Preferred)

Axitinib 5 mg twice daily + pembrolizumab 200 mg IV every 3 weeks is a Category 1, preferred regimen for all IMDC risk groups 7. This combination demonstrated:

• Superior overall survival (HR 0.84) with 5-year follow-up 8
• Median PFS 23.9 months vs 9.2 months with sunitinib 3
• ORR 60.6% vs 39.6% 8

Axitinib 5 mg twice daily + avelumab 10 mg IV every 2 weeks is another first-line option, particularly for PD-L1 positive tumors (median PFS 13.8 vs 7.2 months with sunitinib) 3.

Second-Line Therapy

Axitinib monotherapy is a Category 2B option after failure of one prior systemic therapy 7. The AXIS trial showed median PFS of 6.7 months vs 4.7 months with sorafenib (p<0.0001) 9.

Monotherapy Considerations

First-line axitinib monotherapy is listed as Category 2B (useful in certain circumstances) across all risk groups 7, but combination therapy with checkpoint inhibitors is strongly preferred given superior outcomes.

Monitoring Requirements

Implement this monitoring schedule:

Blood Pressure

• Check before each dose initially, then at least weekly for first 6 weeks
• Target diastolic BP ≥90 mmHg correlates with efficacy 2, 9
• Manage hypertension aggressively with standard antihypertensives; do not discontinue axitinib for controlled hypertension

Laboratory Monitoring

• Liver function tests: Monitor before treatment and periodically during therapy due to risk of hepatotoxicity 1
• Thyroid function (TSH): Check at baseline and periodically; thyroid dysfunction is common 1
• Urinalysis: Monitor for proteinuria 1
• CBC: Monitor for anemia, particularly when combined with pembrolizumab 4

Clinical Assessments

• Assess for bleeding, gastrointestinal symptoms, hand-foot syndrome, and fatigue at each visit
• Monitor for signs of arterial/venous thromboembolism 1

Contraindications and Warnings

Absolute contraindications: None listed in FDA labeling 1.

Critical warnings requiring dose modification or discontinuation:

Cardiovascular (Black Box Equivalent Severity)

• Arterial thromboembolic events: Including MI, stroke, and retinal artery occlusion 1
• Venous thromboembolism: Monitor for DVT/PE 1
• Cardiac failure: Particularly in patients with pre-existing cardiac disease 1
• Major adverse cardiovascular events (MACE): Increased risk documented 1

Gastrointestinal

• GI perforation and fistula formation: Discontinue permanently if these occur 1
• Hemorrhage: Including fatal events; use caution with anticoagulants 1

Other Serious Risks

• Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue if suspected 1
• Impaired wound healing: Hold axitinib at least 24 hours before elective surgery 1
• Embryo-fetal toxicity: Contraception required; pregnancy category D equivalent 1

Common Adverse Effects and Management

The most frequent grade 3+ toxicities are hypertension (16%), diarrhea (11%), and fatigue (11%) 9. In combination with pembrolizumab, 32.3% experienced grade 3+ adverse events 4.

Management Strategies

Hypertension (most common):

• Initiate or uptitrate standard antihypertensives (ACE inhibitors, calcium channel blockers)
• Do not reduce axitinib dose for controlled hypertension
• Only reduce dose if BP remains >150/100 mmHg despite maximal medical management

Diarrhea:

• Initiate loperamide at first sign
• Hold axitinib for grade 3 diarrhea until resolution to grade 1
• Resume at reduced dose

Hand-foot syndrome:

• Prophylactic emollients and keratolytics
• Dose reduction for grade 2-3 symptoms

Fatigue:

• Supportive care; dose reduction if grade 3

Thyroid dysfunction:

• Levothyroxine replacement as needed
• Continue axitinib without dose modification

Dose Modification Algorithm

• Grade 2 adverse events: Continue current dose with supportive care
• Grade 3 adverse events: Hold until resolution to grade ≤1, then resume at reduced dose (5→3→2 mg twice daily)
• Grade 4 adverse events or recurrent grade 3: Discontinue permanently

Alternative Therapies

For first-line advanced clear cell RCC, the following are Category 1 or 2A preferred alternatives:

Combination Immunotherapy

• Nivolumab + ipilimumab: Category 1 for intermediate/poor-risk patients; 52% vs 39% OS probability at 42 months compared to sunitinib 3
• Cabozantinib + nivolumab: Category 1 for all risk groups 7

Other TKI + Checkpoint Inhibitor Combinations

• Lenvatinib + pembrolizumab: Superior to sunitinib with median PFS 23.9 vs 9.2 months 3

Monotherapy Options (Less Preferred)

• Sunitinib: Category 2A for all risk groups 7
• Pazopanib: Category 2A for all risk groups 7

For second-line therapy after TKI failure:

• Cabozantinib: Preferred over axitinib based on METEOR trial showing superior PFS and OS vs everolimus 7
• Nivolumab: Checkpoint inhibitor option if not used first-line

Special Populations at Risk for Early Progression

Patients at high risk for early progression on axitinib include those who:

• Have not undergone nephrectomy (p<0.001)
• Had short duration of response to prior TKI (<6 months)
• Are in IMDC poor-risk category (p<0.001)

For these patients, consider alternative agents (cabozantinib, nivolumab) or closer monitoring with early imaging at 6-8 weeks 10.

Key Clinical Pearls

• Biomarker considerations: Higher T-cell inflamed gene expression profile (TcellinfGEP) and PBRM1 mutations predict better response to axitinib + pembrolizumab 8
• Pharmacokinetics: Short half-life (2.5-6.1 hours) requires strict twice-daily dosing; primarily metabolized by CYP3A4/5 5
• Concomitant anticoagulation: Axitinib can be used with warfarin, but monitor INR closely 6
• Treatment duration: In real-world practice with pembrolizumab combination, median follow-up of 22.6 months showed median PFS of 37.4 months 4